News

QualTex Laboratories, a subsidiary of BioBridge, offers a variety of ways for you to stay connected with us and our subsidiaries. You can read our latest press releases or Annual Reports. Visit the Events Page to find out what’s coming up. You can watch a video clip from a newscast, view past events in the Photo Gallery or read industry news. For the social media enthusiast, the BioBridge family is known as “Connect for Life,” and can be found on FacebookTwitterLinkedIn and YouTube. Also, visit our blog here.

Media is welcome to contact the Corporate Communications Department for more information.

We offer:

  • 
Interviews with experts in their respective medical fields
  • Interviews with Life Links - community members touched by the services of BioBridge Global
  • Informative tours of the facility

Please contact;
Corporate Communications
Phone: (210) 731-5519
Mobile: (210) 296-9026
Email: crd@biobridgeglobal.org

Recent News Articles

February 24, 2016

QualTex Laboratories is working with suppliers and companies affiliated with our parent organization BioBridge Global, and outside laboratories and regulatory agencies to support the development of an effective test for the Zika virus in blood components.

As soon as a test is available, QualTex will work on implementing it for both the South Texas Blood & Tissue Center and customers from coast to coast.

In the meantime, QualTex is monitoring information and sharing it with our customers. We have established a web page updated on a regular basis with news and notes from around the country and around the world.

December 30, 2015

A vaccination for a mosquito-borne virus that has re-emerged in the Caribbean is headed for phase 2 clinical trials.

The National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, is sponsoring trials of a vaccination for the chikungunya virus.

Phase 2 of the trial will enroll 400 adults in the Caribbean, where the virus has re-emerged. The chikungunya virus is spread by mosquito bites, and it can produce severe joint pain, fever and headache that typically last for a week but can persist for months or years.

There have been more than 621,000 cases reported in the Caribbean this year.

December 4, 2015

For the second year in a row, BioBridge Global will be serving as an organizing sponsor of the World Stem Cell Summit. The 2015 summit is next week in Atlanta.

Executives from BBG will be participating in multiple sessions at the event, which is coordinated by the Genetic Policy Institute and runs Dec. 10-12. BioBridge Global was an organizing sponsor of the 2014 summit, which was in San Antonio.

BBG subsidiary QualTex Laboratories operates a major facility in the Atlanta metro area.

October 26, 2015

Changing just one letter of the DNA of red blood cells holds the promise for a cure to sickle cell anemia and similar blood disorders, Australian researchers have found.

A study at the University of New South Wales shows that a single genetic modification – which essentially switches on a gene that is sleeping in most people after birth – can increase the production of oxygen-carrying hemoglobin.

“An exciting new age of genome editing is beginning, now that single genes within our vast genome can be precisely cut and repaired,” Merlin Crossley, Dean of Science at the university and the lead researcher in the study, said in a university news release.

September 14, 2015

A simple blood test could replace expensive and often-invasive biopsies for detecting cancer, according to research presented recently by researchers from the United Kingdom.

A blood test to establish the presence of cancerous cells would offer a quicker diagnosis at a fraction of the cost of a biopsy, said Eric Lim, consultant thoracic surgeon at Royal Brompton & Harefield National Health Service Foundation Trust.

A 2014 report showed the typical biopsy cost more than $14,000.

The UK study involved blood testing of 223 patients with known or suspected primary or secondary lung cancer. The test was accurate in almost 70 percent of the cases.

The test detects three cancer-specific gene mutations in the bloodstream. The researchers said similar gene patterns in lung and colorectal cancer would make the test useful for finding both forms of cancer.

Pages